Special Issue

Gut Microbiota Modulation: Probiotics, Postbiotics and other Bioactive Compounds

Message from the Guest Editors

In recent years, gut microbiota has been intensively explored at various levels. With the advent of multiomics techniques such as metagenomics and metatranscriptomics, the structure and function of the microbiota have begun to be understood. Given that 70–80% of immune cells are found in the gut, it is clear what a major impact this "super organ" has on health. Topics to be covered within this Special Issue include (but are not limited to):

- Novel probiotic strains;
- Influence of probiotics and/or bioactive compounds on gut microbiota modulation;
- Influence of probiotics and/or bioactive compounds in health and disease states;
- Signaling pathways mediating probiotics-host effects;
- Safety and regulations for the use of probiotics;
- Bioactive compounds able to modulate the gut microbiota and generated by fermentation/enzyme hydrolyses or food processing methods.

Contributions of original research to review articles are welcome.

Guest Editors

Dr. Inês Brandão

Centro de Apoio Tecnológico Agro Alimentar (CATAA) de Castelo Branco, 6000-459 Castelo Branco, Portugal

Dr. Christophe Ruis Espírito Santo

Centro de Apoio Tecnológico Agro Alimentar (CATAA) de Castelo Branco, 6000-459 Castelo Branco, Portugal

Deadline for manuscript submissions

closed (25 May 2025)



Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/146533

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/ pharmaceuticals





Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Cièncias, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

